Kissinger Financial Services LLC boosted its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 31.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,776 shares of the biopharmaceutical company’s stock after acquiring an additional 1,838 shares during the quarter. Kissinger Financial Services LLC’s holdings in Bristol-Myers Squibb were worth $433,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Toronto Dominion Bank boosted its position in Bristol-Myers Squibb by 54.0% during the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after acquiring an additional 162,884 shares during the period. Mutual of America Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 1.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after buying an additional 3,833 shares during the last quarter. Meridian Management Co. lifted its holdings in shares of Bristol-Myers Squibb by 1.5% during the 1st quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock valued at $2,815,000 after buying an additional 770 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $6,150,000. Finally, Tobam lifted its holdings in shares of Bristol-Myers Squibb by 124.5% during the 1st quarter. Tobam now owns 793,714 shares of the biopharmaceutical company’s stock valued at $43,163,000 after buying an additional 440,170 shares during the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.
Several brokerages have recently issued reports on BMY. Cowen and Company reiterated a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price target for the company in a report on Thursday, August 17th. Finally, William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $62.20.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) remained flat at $63.49 on Thursday. The company had a trading volume of 2,174,474 shares. The stock has a market cap of $104.12 billion, a price-to-earnings ratio of 23.19 and a beta of 1.18. The company’s 50-day moving average price is $58.94 and its 200 day moving average price is $56.02. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $63.74.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the firm posted $0.69 earnings per share. The business’s revenue was up 5.6% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be given a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.46%. Bristol-Myers Squibb’s payout ratio is 56.73%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.